Contrave Extended-Release is a Oral Tablet, Extended Release in the Human Prescription Drug category. It is labeled and distributed by Nalpropion Pharmaceuticals Llc. The primary component is Naltrexone Hydrochloride; Bupropion Hydrochloride.
| Product ID | 51267-890_74062009-01b3-4270-9080-139e0f0e29c9 |
| NDC | 51267-890 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Contrave Extended-Release |
| Generic Name | Naltrexone Hydrochloride And Bupropion Hydrochloride |
| Dosage Form | Tablet, Extended Release |
| Route of Administration | ORAL |
| Marketing Start Date | 2014-10-22 |
| Marketing Category | NDA / NDA |
| Application Number | NDA200063 |
| Labeler Name | Nalpropion Pharmaceuticals LLC |
| Substance Name | NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE |
| Active Ingredient Strength | 8 mg/1; mg/1 |
| Pharm Classes | Opioid Antagonist [EPC],Opioid Antagonists [MoA],Aminoketone [EPC],Dopamine Uptake Inhibitors [MoA],Increased Dopamine Activity [PE],Increased Norepinephrine Activity [PE],Norepinephrine Uptake Inhibitors [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 2014-10-22 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA200063 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Marketing Start Date | 2014-09-10 |
| Marketing End Date | 2017-05-17 |
| Marketing Category | NDA |
| Application Number | NDA200063 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 2014-10-22 |
| Ingredient | Strength |
|---|---|
| NALTREXONE HYDROCHLORIDE | 8 mg/1 |
| SPL SET ID: | 485ff360-32c8-11df-928b-0002a5d5c51b |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 43063-772 | Contrave | naltrexone hydrochloride and bupropion hydrochloride |
| 50090-2868 | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride |
| 50090-2945 | Contrave | naltrexone hydrochloride and bupropion hydrochloride |
| 51267-890 | Contrave | naltrexone hydrochloride and bupropion hydrochloride |
| 64764-890 | CONTRAVE | naltrexone hydrochloride and bupropion hydrochloride |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() CONTRAVE 86026234 5181874 Live/Registered |
Orexigen Therapeutics, Inc. 2013-08-01 |
![]() CONTRAVE 78979619 3393576 Live/Registered |
NALPROPION PHARMACEUTICALS LLC 2006-01-06 |
![]() CONTRAVE 78794374 not registered Dead/Abandoned |
AGrow Tech LLC 2006-01-18 |
![]() CONTRAVE 78786858 not registered Dead/Abandoned |
Orexigen Therapeutics, Inc. 2006-01-06 |
![]() CONTRAVE 77926232 not registered Dead/Abandoned |
Orexigen Therapeutics, Inc. 2010-02-02 |
![]() CONTRAVE 77925784 not registered Dead/Abandoned |
Orexigen Therapeutics, Inc. 2010-02-02 |
![]() CONTRAVE 77811077 not registered Dead/Abandoned |
Orexigen Therapeutics, Inc. 2009-08-24 |